pipeline-prospector-insert
X

Find Approved Oncology Drugs in Clinical Development in UNITED STATES

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Enzalutamide,Androgen deprivation therapy

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Astellas Pharma

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 29, 2020

            Details:

            Phase 3 PROSPER trial evaluating XTANDI® (enzalutamide) plus androgen deprivation therapy (ADT) vs placebo plus ADT in men with non-metastatic castration-resistant prostate cancer, revealed that XTANDI plus ADT reduced the risk of death by 27% compared to placebo plus ADT.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lorlatinib

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 13, 2020

            Details:

            The drug has been recommended as an option for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) in adults whose disease has progressed after: alectinib or ceritinib or crizotinib.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Avapritinib

            Therapeutic Area: Oncology Product Name: Ayvakit

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 29, 2020

            Details:

            The Lancet Oncology published data from the NAVIGATOR clinical trial showed an unprecedented overall survival (OS) rate and a well-tolerated safety profile for AYVAKIT™ (avapritinib) in patients with advanced PDGFRA D842V mutant gastrointestinal stromal tumor (GIST).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Rituximab

            Therapeutic Area: Oncology Product Name: Ruxience

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Pfizer Inc

            Deal Size: $0.7 million Upfront Cash: Undisclosed

            Deal Type: Financing June 25, 2020

            Details:

            This collection relates to the Company's sale of its Hemophilia B therapy, IXINITY®, to Medexus Pharmaceuticals.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Daratumumab,Recombinant human hyaluronidase PH20 enzyme

            Therapeutic Area: Oncology Product Name: Darzalex

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Janssen Pharmaceutical

            Deal Size: $10.0 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement June 22, 2020

            Details:

            The milestone payment is associated with the first commercial sale in the European Union of Janssen's subcutaneous formulation of DARZALEX® (daratumumab) utilizing ENHANZE®, which was recently granted marketing authorization by the European Commission.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tazemetostat

            Therapeutic Area: Oncology Product Name: Tazverik

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 18, 2020

            Details:

            The sNDA for TAZVERIK™ is approved for two distinct follicular lymphoma (FL) indications: Adult patients with relapsed or refractory FL whose tumors are positive for an EZH2 mutation, Patients with relapsed/refractory FL who have no satisfactory alternative treatment options.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tivozanib

            Therapeutic Area: Oncology Product Name: Fotivda

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: SVB Leerink

            Deal Size: $44.6 million Upfront Cash: Undisclosed

            Deal Type: Public Offering June 16, 2020

            Details:

            The net proceeds of the offering are expected to be used for working capital and general corporate purposes, including funding commercialization activities relating to tivozanib.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Venetoclax,Azacitidine

            Therapeutic Area: Oncology Product Name: Venclexta

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Genentech

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 13, 2020

            Details:

            Phase 3 VIALE-A study showed a 34 percent reduction in the risk of death in AML patients who were ineligible for intensive chemotherapy treated with venetoclax plus azacitidine compared to azacitidine plus placebo.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tagraxofusp

            Therapeutic Area: Oncology Product Name: Elzonris

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Menarini

            Deal Size: $677.0 million Upfront Cash: $677.0 million

            Deal Type: Acquisition June 10, 2020

            Details:

            Acquisition establishes Menarini’s presence in the U.S. biopharmaceutical oncology market. Menarini will support further development of Stemline’s ELZONRIS and enable global expansion by leveraging its commercial infrastructure in Europe and other ex-U.S. geographies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Nivolumab

            Therapeutic Area: Oncology Product Name: Opdivo

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 10, 2020

            Details:

            This application was granted Priority Review Designation by the FDA, and the approval is based on the Phase 3 ATTRACTION-3 trial in which Opdivo demonstrated superior overall survival vs taxane chemotherapy.

            PharmaCompass